CellSeed Inc. (JP:7776)
:7776
Want to see JP:7776 full AI Analyst Report?
7776 Stock Chart & Stats
¥259.00
-¥7.00(-1.73%)
At close: 4:00 PM EST
¥259.00
-¥7.00(-1.73%)
Day’s Range― - ―
52-Week Range¥222.00 - ¥549.00
Previous CloseN/A
Volume900.50K
Average Volume (3M)621.90K
Market Cap
¥8.69B
Enterprise Value¥7.80B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.24
Shares Outstanding39,160,420
10 Day Avg. Volume981,780
30 Day Avg. Volume621,903
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)7.08
Price to Sales (P/S)107.39
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Niche Regenerative TechnologySpecialization in cell sheet engineering and regenerative cell therapies gives the company a durable technical moat in a high-barrier subsector. Clinical and manufacturing know-how, IP and specialized services support long-term partnership, licensing and commercial opportunities versus generalist biotech peers.
Healthy Gross MarginsSustained gross margins near mid-to-high single digits for biotech indicate solid unit economics and pricing power for products/services. These margins support the ability to fund R&D and scale manufacturing more efficiently if revenue recovers, improving long-term profitability potential.
Conservative Financial LeverageLow leverage reduces solvency risk during multi-year clinical or commercialization cycles, preserving flexibility to raise non-debt capital or invest in operations. Conservative debt levels lengthen runway versus highly leveraged peers and lower restructuring risk if revenues remain volatile.
Bears Say
Sharp Revenue DeteriorationA marked revenue decline erodes the base needed to absorb fixed R&D and manufacturing costs, signaling execution, demand or product-timing issues. Persistently lower top-line reduces operating leverage, lengthens time to breakeven, and weakens the fundamentals that underpin long-term growth.
Persistent Cash BurnContinuous negative operating and free cash flow forces reliance on external financing or dilution to fund operations. In a capital-intensive biotech model, ongoing cash burn without a clear path to self-funding increases refinancing risk and can constrain R&D, trials or commercialization investments.
Very Large Losses And Equity ErosionExtreme negative margins and declining equity reflect sustained structural unprofitability that erodes balance sheet strength. Continued losses raise dilution risk, weaken investor confidence and limit strategic options, making long-term viability dependent on substantial operational improvement or external funding.
CellSeed Inc. News
7776 FAQ
What was CellSeed Inc.’s price range in the past 12 months?
CellSeed Inc. lowest stock price was ¥222.00 and its highest was ¥549.00 in the past 12 months.
What is CellSeed Inc.’s market cap?
CellSeed Inc.’s market cap is ¥8.69B.
When is CellSeed Inc.’s upcoming earnings report date?
CellSeed Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 68 days.
How were CellSeed Inc.’s earnings last quarter?
CellSeed Inc. released its earnings results on May 13, 2026. The company reported -¥7.24 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.24.
Is CellSeed Inc. overvalued?
According to Wall Street analysts CellSeed Inc.’s price is currently Overvalued.
Does CellSeed Inc. pay dividends?
CellSeed Inc. does not currently pay dividends.
What is CellSeed Inc.’s EPS estimate?
CellSeed Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSeed Inc. have?
CellSeed Inc. has 39,160,420 shares outstanding.
What happened to CellSeed Inc.’s price movement after its last earnings report?
CellSeed Inc. reported an EPS of -¥7.24 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.916%.
Which hedge fund is a major shareholder of CellSeed Inc.?
Currently, no hedge funds are holding shares in JP:7776
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSeed Inc.
CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass epithelial cell sheets for repairing the esophagus, as well as both regenerated cartilage sheets and chondrocyte sheets aimed at addressing knee osteoarthritis. Beyond its therapeutic pipeline, CellSeed manufactures and distributes a range of specialized cell cultureware. This includes UpCell, a temperature-responsive cultureware vital for cell-sheet engineering; RepCell, another temperature-sensitive product designed for efficient cell collection; and HydroCell, distinguished by its low cell-binding properties. The firm also provides supporting equipment, such as ThermoPlate III, a heating element constructed from transparent glass, and cellZscope, an automated system for real-time cell monitoring. Additionally, CellSeed offers contract development and manufacturing services. Founded in 2001, the company's main operations are situated in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
StemCell Institute
―
Japan Tissue Engineering Co., Ltd.
―